$APLS News

Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum

Apellis Pharmaceuticals (NASDAQ:APLS): Strong Growth Stock with a Technical Breakout Setup

Apellis Pharmaceuticals Q1 EPS $0.15 Beats $(0.36) Estimate, Sales $268.295M Beat $205.185M Estimate

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS): A Fitting GARP Opportunity

Apellis Pharmaceuticals Inc (NASDAQ:APLS) Emerges as a Growth Stock with Bullish Technical Breakout Potential

Wells Fargo Downgrades Apellis Pharmaceuticals to Equal-Weight, Raises Price Target to $41

Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate

Mizuho Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $41

Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry

JP Morgan Downgrades Apellis Pharmaceuticals to Neutral, Raises Price Target to $41

Barclays Maintains Equal-Weight on Apellis Pharmaceuticals, Raises Price Target to $41

Raymond James Downgrades Apellis Pharmaceuticals to Market Perform

Citigroup Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $41

HC Wainwright & Co. Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $41

Needham Downgrades Apellis Pharmaceuticals to Hold

Apellis Pharmaceuticals share are trading higher after the company announced that it will be acquired by Biogen for $41 per share.

Apellis Pharmaceuticals share are trading higher after the company announced that it will be acquired by Biogen for $41 per share.

Cantor Fitzgerald Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $31

Roth Capital Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $31

JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $37